Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Michel Lanteri-Minet
096 Assessment of the Efficacy of Erenumab During the Open-Label Treatment (13–24 Weeks) of Subjects With Episodic Migraine Who Failed 2–4 Prior Preventive Treatments: Results of the LIBERTY Study
Journal of Neurology, Neurosurgery and Psychiatry
Psychiatry
Mental Health
Neurology
Surgery
Managing Cluster Headache With Sphenopalatine Ganglion Stimulation: A Review
Journal of Pain Research
Anesthesiology
Pain Medicine
Related publications
Pnd141 - Characteristics and Management of Migraine Patients Who Have Failed Prior Preventive Treatment in Portugal
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
An Open-Label Pilot Study on the Efficacy and Tolerability of Levetiracetam in the Prophylaxis of Migraine
Journal of Headache and Pain
Medicine
Neurology
Anesthesiology
Pain Medicine
Pnd67 - Are New Preventive Migraine Drugs Cost-Effective for Patients With Chronic and Episodic Migraine for Whom Other Preventive Medications Had Failed?
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Long-Term Efficacy and Safety of RPC4046, an Anti-Interleukin-13 Monoclonal Antibody, in Patients With Eosinophilic Esophagitis: Results From the Open-Label Extension of the HEROES Study
Journal of Allergy and Clinical Immunology
Allergy
Immunology
Efficacy of Pregabalin Versus Nortriptyline in the Treatment of Chronic Low Backache With Radiculopathy: An Open Label Observational Study
International Journal of Basic & Clinical Pharmacology
The Liberty of Open Access
PLAID: People Living with And Inspired by Diabetes
Ineffective Acute Treatment of Episodic Migraine Is Associated With New-Onset Chronic Migraine
Neurology
Neurology
Fremanezumab for Preventive Treatment of Migraine
Neurology
Neurology
Efficacy and Tolerability of Escitalopram in Treatment of Major Depressive Disorder With Anxiety Symptoms: A 24-Week, Open-Label, Prospective Study in Chinese Population
Neuropsychiatric Disease and Treatment
